111 (YI) Stock News

111, Inc. (NASDAQ: YI) has formed a Special Committee comprising three independent directors to evaluate a preliminary non-binding proposal dated September 9, 2022, and potential strategic alternatives. The committee has engaged Houlihan Lokey China Limited as an independent financial advisor and Kirkland & Ellis as U.S. legal counsel. The Board advises shareholders that no decisions regarding the Proposal or any alternatives have yet been made, and no assurance is provided for any definitive agreements. The company continues to focus on connecting patients with healthcare services through its innovative platforms.

111 Inc. (NASDAQ: YI), a tech-enabled healthcare platform in China, announced that its Board has received an unsolicited preliminary non-binding proposal from Co-Founders Dr. Gang Yu and Mr. Junling Liu, along with Shanghai Guosheng Capital, to acquire all outstanding Class A shares at US$1.83 per share or US$3.66 per ADS. The proposal intends to fund the acquisition through equity capital, including cash contributions from the Sponsor. The Board has yet to evaluate the proposal, emphasizing no assurance of a definitive offer or agreement will occur.

111, Inc. (NASDAQ: YI) reported its unaudited financial results for Q2 2022, showcasing net revenues of RMB3.04 billion (US$453.4 million), up 0.4% YOY. Gross segment profit surged by 42.6%, with the B2B segment profit rising 55.1%. Operating expenses decreased to RMB271.7 million (US$40.6 million), down from RMB323.4 million last year, marking an improvement in operational efficiency. Despite challenges from COVID-19 lockdowns in Shanghai, non-GAAP loss from operations narrowed to RMB52.8 million (US$7.9 million), or 1.7% of net revenues, indicating progress towards profitability.

111, Inc. (NASDAQ: YI) will report its Q2 2022 unaudited financial results before U.S. markets open on August 25, 2022. An earnings conference call is scheduled for 7:30 AM U.S. Eastern Time on the same day. Participants must register online to receive dial-in details. 111, Inc. is a tech-enabled healthcare platform in China, connecting patients with pharmaceutical products and healthcare services through its online pharmacy and digital health services.

111, Inc. (NASDAQ: YI) reported first quarter 2022 financial results, achieving net revenues of RMB2.98 billion (US$470.5 million), a 14.9% year-over-year increase. Gross segment profit surged by 66.3%, with the B2B segment profit rising by 90.7%. Total operating expenses declined as a percentage of revenues to 9.9%. Non-GAAP loss from operations decreased to RMB72.4 million (US$11.4 million), or 2.4% of revenues. The company noted an increase in pharmaceutical partnerships to 550, reflecting strong market growth despite pandemic challenges.

111, Inc. (NASDAQ: YI) announced it will release its unaudited financial results for Q1 2022 on June 16, 2022, before U.S. market opens. The company's management will hold an earnings conference call at 7:30 AM ET on the same day, with registration required for participation. 111, Inc. operates a digital healthcare platform in China, connecting patients to medicine and healthcare services through its online pharmacy and internet hospital. The company offers various healthcare services, enhancing accessibility and efficiency for consumers.

On May 4, 2022, 111 Inc. (NASDAQ: YI) was provisionally listed as a "Commission-Identified Issuer" by the SEC under the Holding Foreign Companies Accountable Act. This follows the filing of its annual report on Form 20-F for the year ended December 31, 2021. The SEC's identification indicates that the Company used an auditor whose working papers are not fully inspectable by the PCAOB. If this is not addressed, trading of its securities may be prohibited on U.S. exchanges after three years. 111 Inc. is committed to maintaining compliance and protecting shareholder interests.

On April 13, 2022, 111, Inc. (NASDAQ: YI) announced its establishment of an 'Anti-Epidemic Command' to aid in Shanghai's COVID-19 response. The company has implemented various services including antigen test supplies, chronic disease medication registration, and online consultations. Following an initial shipment of essential items on April 7, 111 has enhanced its logistics for fast delivery. The online platform, 1 Pharmacy, offers over 100,000 drugs, while 1 Clinic provides virtual consultations. Dr. Yu Gang emphasized the company's commitment to support Shanghai's healthcare needs during the pandemic.

111, Inc. (YI) reported its Q4 and full-year 2021 financial results, highlighting a 30.9% YoY increase in net revenues to RMB 3.46 billion (US$ 543.1 million) for Q4, and a 51.5% YoY increase to RMB 12.4 billion (US$ 1.95 billion) for the fiscal year. Gross segment profit surged 98% YoY in Q4, with a 70% increase annually. Notably, the company expanded its partnerships to 515 pharmaceutical companies. Despite a non-GAAP loss from operations of RMB 76.9 million (US$ 12.1 million), the loss margin improved significantly from 4.2% to 2.2% YoY.